Prognostic value of pre-operative assesment of serum carcino-embryonic antigen and carbohydrate antigen 19-9 levels in colorectal carcinoma

Qatar Medical Journal

Volumn 16, Issue 2, 2007, Pages 12-15

  Abel Rahman, E M ^a   El Gonimy, A A ^b   Farouk, S ^b  

^a AL AZHAR UNIVERSITY   (Egypt)

^b Banha Teaching Hospital   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON TUMOR; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECTUM TUMOR; SEX DIFFERENCE; TUMOR LOCALIZATION;

EID: 53849142598     PISSN: 02538253     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. De Cosse JJ, Tasiolias GJ, Jacobson J.S. Colorectal Cancer 1 detection, treatment and rehabilitation. Cancer- Cancer J Clin (1994); 44:27-42.
2. Knopf K B, Warren JI, Feuer E J, Brown ML. Bowel surveillance pattern after a diagnosis of colorectal cancer in Medicare beneficiaries. American Society for Gastroenterology endoscopy (2001); Vol. 54, No. 5.
3. Thomas WM, Robertson JFR, Hardcastle JD. Failure of CA 19-9 to detect asymptomatic colorectal carcinoma. Br. J. Cancer (1991), 63, 975-976.
4. Reiter W, stieber P, Renter C, et al. Multivariate analysis of prognostic value of CEA and CA 19-9 serum levels in colorectal carcinoma. Anticancer Res (2000), Dec, No. 20 (61): 5195-8.
5. Kim FC, Rob SA, Kim H C, Koo KH, and Cob YK, et al. Co-expression of Carcinoembryonic Antigen and E-cadherin in Colorectal Adeno-carcinoma with liver metastasis. Gastrointestinal Surg (2003); 7: 931-938.
6. Dixon MR, Haukoos JS, Udani SM, and Naghi JJ, et al. Carcinoembryonic Antigen and Albumin Predict Survival in Patients With Advanced Colon and Rectal Cancer. Arch Surg (2003); 138: 962-966.
7. Shimono R, Mori M, Akazawak K, et al. Immunohistochemical Expression of carbohydrate antigen 19-9 in colorectal carcinoma. American J of Gastroenterology (1994), Vol. 89, No. 1, 101-105.
8. Mroczko B, Szmitkowski M, and Okulczyk, et al. Hematopoitic Growth Factor in Colorectal Cancer Patients. Clin Chem. Lab Med. (2003); (41) 5: 646-651.
9. Kuo LJ, Leu SY, Liu MC, et al. How aggressive should we be in patients with Stage IV colorectal carcinoma? Dis Colon, Rectum, Dec (2003); 46:1646-1652.
10. Yukawa N, Yoshikawa T, Akaike M, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br.J. of Surgery (2001), 88, 1596-1601.
11. Horie Y, Miura K, Mastui K, et al. Marked elevation of plasma CEA and stomach cancer. Cancer (1996); 77: 1991-7
12. Sears HF, Herlyn M, Villano D, et al. Monoclonal antibody detection of circulating tumor associated antigen II. Longitudinal evaluation of patients with colorectal carcinoma. J. Clin, Immunol (1982), 2, 141.
13. Mineo TC, Ambrogi V, Tonini G, et al. Long-term results after resection of simultaneous and sequential lung and liver metastasis from colorectal carcinoma. American College of Surgery (2003), Sept, Vol. 197, No. 3.
14. Kuusela P, Jalanko H, Robert SP, et al. Plasma concentration of tissue inhibitor 1 in patients with colorectal carcinoma. Br J. of Surgery (2001), 88, 1596-1601.